Pages that link to "Q28484922"
Jump to navigation
Jump to search
The following pages link to Enhanced antitumor efficacy and reduced systemic toxicity of sulfatide-containing nanoliposomal doxorubicin in a xenograft model of colorectal cancer (Q28484922):
Displaying 9 items.
- Use of rodents as models of human diseases (Q26822856) (← links)
- Effect of doxorubicin/pluronic SP1049C on tumorigenicity, aggressiveness, DNA methylation and stem cell markers in murine leukemia (Q27309004) (← links)
- Improved efficacy and reduced toxicity of doxorubicin encapsulated in sulfatide-containing nanoliposome in a glioma model (Q28541327) (← links)
- Development of antiproliferative long-circulating liposomes co-encapsulating doxorubicin and curcumin, through the use of a quality-by-design approach. (Q33739032) (← links)
- Co-encapsulation of Doxorubicin with galactoxyloglucan nanoparticles for intracellular tumor-targeted delivery in murine ascites and solid tumors. (Q34478394) (← links)
- Delivery of suramin as an antiviral agent through liposomal systems (Q35116944) (← links)
- Application of liposomes in drug development--focus on gastroenterological targets (Q36758275) (← links)
- Nanoliposomal artemisinin for the treatment of murine visceral leishmaniasis (Q37722715) (← links)
- Liposomal Nanostructures for Drug Delivery in Gastrointestinal Cancers (Q90437022) (← links)